NELFE-Dependent MYC Signature Identifies a Unique Cancer Subtype in Hepatocellular Carcinoma

The MYC oncogene is dysregulated in approximately 30% of liver cancer. In an effort to exploit MYC as a therapeutic target, including in hepatocellular carcinoma (HCC), strategies have been developed on the basis of MYC amplification or gene translocation. Due to the failure of these strategies to p...

Descripción completa

Detalles Bibliográficos
Autores principales: Dang, Hien, Pomyen, Yotsawat, Martin, Sean P., Dominguez, Dana A., Yim, Sun Young, Lee, Ju-Seog, Budhu, Anuradha, Shah, Ashesh P., Bodzin, Adam S., Wang, Xin Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399236/
https://www.ncbi.nlm.nih.gov/pubmed/30833661
http://dx.doi.org/10.1038/s41598-019-39727-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399236/
https://www.ncbi.nlm.nih.gov/pubmed/30833661
http://dx.doi.org/10.1038/s41598-019-39727-9

Ejemplares similares